Patients should understand that while the medication itself won't show up on blood tests, the therapeutic effects of GLP-1 drugs are clearly evident through improved metabolic markers: lower HbA1c, reduced fasting glucose, potential improvements in lipid profiles, and weight loss
The FDA will enforce these rules more
The MHRA has not granted marketing authorisation for retatrutide
'The community is done' Nearly as soon as the first word left Forrests mouth Monday night, Pooler residents were on the defensive
According to the MHRA/EMC Summary of Product Characteristics (SmPC), dizziness is classified as an 'uncommon' side effect, affecting fewer than 1 in 100 patients
Symptoms can include severe abdominal pain, heavy bleeding, or pain during sex